ABEO — Abeona Therapeutics Share Price
- $288.91m
- $184.55m
- $3.50m
- 20
- 14
- 95
- 39
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.94 | ||
Price to Tang. Book | 3.94 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -48.43% | ||
Return on Equity | -127.38% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | 10 | 3 | 1.41 | 3.5 | 0.2 | 14.39 | 3.14% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Directors
- Michael Amoroso CHM (43)
- Vishwas Seshadri PRE (46)
- Edward Carr CFO (51)
- Brendan O Malley SVP
- Brian Kevany VPR
- Christine Silverstein DRC (38)
- Leila Alland IND (58)
- Mark Alvino IND (53)
- Faith Charles IND (59)
- Paul Mann IND (45)
- Todd Wider IND (56)
- Donald Wuchterl IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 22nd, 1989
- Public Since
- September 19th, 1980
- No. of Shareholders
- 248
- No. of Employees
- 84
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 43,314,397
- Address
- 6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, 44103
- Web
- https://abeonatherapeutics.com/
- Phone
- +1 6468134701
- Auditors
- Whitley Penn LLP
Upcoming Events for ABEO
Q4 2024 Abeona Therapeutics Inc Earnings Release
Similar to ABEO
180 Life Sciences
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 19:02 UTC, shares in Abeona Therapeutics are trading at $6.67. This share price information is delayed by 15 minutes.
Shares in Abeona Therapeutics last closed at $6.67 and the price had moved by +55.84% over the past 365 days. In terms of relative price strength the Abeona Therapeutics share price has outperformed the S&P500 Index by +12.25% over the past year.
The overall consensus recommendation for Abeona Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAbeona Therapeutics does not currently pay a dividend.
Abeona Therapeutics does not currently pay a dividend.
Abeona Therapeutics does not currently pay a dividend.
To buy shares in Abeona Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.67, shares in Abeona Therapeutics had a market capitalisation of $288.91m.
Here are the trading details for Abeona Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ABEO
Based on an overall assessment of its quality, value and momentum Abeona Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abeona Therapeutics is $15.92. That is 138.68% above the last closing price of $6.67.
Analysts covering Abeona Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.56 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abeona Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -24.72%.
As of the last closing price of $6.67, shares in Abeona Therapeutics were trading +18.92% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abeona Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abeona Therapeutics' management team is headed by:
- Michael Amoroso - CHM
- Vishwas Seshadri - PRE
- Edward Carr - CFO
- Brendan O Malley - SVP
- Brian Kevany - VPR
- Christine Silverstein - DRC
- Leila Alland - IND
- Mark Alvino - IND
- Faith Charles - IND
- Paul Mann - IND
- Todd Wider - IND
- Donald Wuchterl - IND